The aim of this paper is to describe the possible effects of antipsychotic drugs on neurotransmitter interactions in cortico-striatal circuits related to schizophrenia symptoms, with special emphasis on the action of partial agonists of dopamine and serotonin receptors.
Partial agonists are characterised by a high affinity and a low intrinsic activity. However, since the intrinsic activity of the ligand-bound receptor is still higher than after antagonist binding, partial agonists can act as agonists or as antagonists, depending on the endogenous levels of dopamine and receptor reserve. Aripiprazole is a partial agonist at dopamine D2-receptors and at serotonin 1A-receptors, and is currently the only marketed drug of this class of agents that is used for the treatment of schizophrenia.
References
1
Abi-Dargham A, Gil R, Krystal J, Baldwin RM, Seibyl JP, Bowers M, Dyck CH van, Charney DS, Innis RB, Laruelle M.
Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort.
Am J Psychiatry.
1998;
155
761-767
2
Abi-Dargham A, Mawlawi O, Lombardo I, Gil R, Martinez D, Huang Y, Hwang D-R, Keilp J, Kochan L, Van Heertum R, Gorman JM, Laruelle M.
Prefrontal dopamine D1 receptors and working memory in schizophrenia.
J Neurosci.
2002;
22
3708-3719
4
Andrezina R, Josiassen RC, Marcus RN, Oren DA, Manos G, Stock E, Carlson WH, Iwamoto T.
Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol.
Psychopharmacology.
2006;
188
281-292
5
Bortolozzi A, Diaz-Mataix L, Toth M, Celada P, Artigas F.
In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain.
Psychopharmacology.
2007;
191
745-758
6
Callicott JH, Mattay VS, Verchinski BA, Egan MF, Weinberger DR.
Complexity of prefrontal cortical dysfunction in schizophrenia: more than up or down.
Am J Psychiatry.
2003;
160
2209-2215
8
Carlsson A, Waters N, Holm-Waters S, Tedroff J, Nilsson M, Carlsson ML.
Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence.
Annu Rev Pharmacol Toxicol.
2001;
41
237-260
12
Cutler AJ, Marcus RN, Hardy SA, O'Donnell A, Carson WH, MacQuade RD.
The efficacy and safety of lower doses of aripiprazole for the treatment of patients with acute exacerbation of schizophrenia.
CNS Spectr.
2006;
11
691-702
16
Farde L, Nordström AL, Wiesel FA, Pauli S, Halldin C, Sedvall G.
Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects.
Arch Gen Psychiatry.
1992;
49
538-544
21
Gründer G, Kungel M, Ebrecht M, Göröcs T, Modell S.
Aripiprazole: Pharmacodynamics of a dopamine partial agonist for the treatment of schizophrenia.
Pharmacopsychiatry.
2006;
39
S21-S25
23
Harrison PJ, Weinberger DR.
Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence.
Mol Psychiatry.
2005;
10
40-68
25
Ichikawa J, Li Z, Dai J, Meltzer HY.
Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism.
Brain Res.
2002;
956
349-357
26
Kane JM, Carson WH, Saha AH, MacQuade RD, Ingenito GG, Zimbroff DL, Ali MW.
Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.
J Clin Psychiatry.
2002;
63
763-771
28
Kern RS, Green MF, Cornblatt BA, Owen JR, MacQuade RD, Carson WH, Ali M, Marcus R.
The neurocognitive effects of aripiprazole: an open-label comparison with olanzapine.
Psychopharmacology.
2006;
187
312-320
32
Li Z, Ichikawa J, Dai J, Meltzer HY.
Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain.
Eur J Pharmacol.
2004;
493
75-83
34
Marder SR, MacQuade RD, Stock EG, Kaplita SB, Marcus R, Safferman AZ, Saha A, Ali MW, Iwamoto T.
Aripiprazole in the treatment of schizophrenia: safety and tolerabilityin short-term, placebo-controlled trials.
Schizophr Res.
2003;
61
123-136
35
Meller E, Bohmaker K, Namba Y, Friedhoff AJ, Goldstein M.
Relationship between receptor occupancy and responses at striatal dopamine autoreceptors.
Mol Pharmacol.
1987;
31
592-598
36
Miyamoto S, Duncan GE, Marx CE, Lieberman JA.
Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs.
Mol Psychiatry.
2005;
10
79-104
38
Nicola SM, Surmeier DJ, Malenka RC.
Dopaminergic modulation of neuronal excitability in the striatum and nucleus accumbens.
Annu Rev Neurosci.
2000;
23
185-215
39
Okubo Y, Suhara T, Suzuki K, Kobayashi K, Inoue O, Terasaki O, Someya Y, Sassa T, Sudo Y, Matsushima E, Iyo M, Tateno Y, Toru M.
Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET.
Nature.
1997;
385
634-636
40
Pigott TA, Carlson WH, Saha AR, Torbeyns AF, Stock EG, Ingenito GG.
Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study.
J Clin Psychiatry.
2003;
64
1048-1056
41
Pilla M, Perachon S, Sautel F, Garrido F, Mann A, Wermuth C, Schwarcz J-C, Everitt BJ, Sokoloff P.
Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist.
Nature.
1999;
400
371-375
42
Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E, Stringfellow J, Ingenito G, Marder SR.
Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder.
Arch Gen Psychiatry.
2003;
60
681-690
44
Schwabe K, Koch M.
Effects of aripiprazole on operant responding for a natural reward after psychostimulant withdrawal in rats.
Psychopharmacology.
2007;
191
759-765
51
Yokoi F, Grunder G, Biziere K, Stephane M, Dogan AS, Dannals RF, Ravert H, Suri A, Bramer S, Wong DF.
Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597) a study using positron emission tomography and [11C] raclopride.
Neuropsychopharmacology.
2002;
27
248-259
52
Zocchi A, Fabbri D, Heidbreder CA.
Aripiprazole increases dopamine but not noradrenaline and serotonin levels in the mouse prefrontal cortex.
Neurosci Lett.
2005;
387
157-161